View Post

Tyme Technologies Begins Cancer Metabolism-Based Therapy Trial in Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Tyme Technologies said on Monday it has dosed the first patient in its Phase II OASIS trial of SM-88 in previously treated metastatic hormone receptor (HR)-positive HER2-negative breast cancer patients. The investigator-initiated study at Georgetown University will initially enroll 30 patients with metastatic HR-positive HER2-negative breast cancer who have previously received at least two lines …

View Post

Study of SM-88 Shows Promising Results in Advanced Pancreatic Cancer

In Clinical Studies News by Barbara Jacoby

By: Gina Columbus From: targetedonc.com The investigational agent SM-88 demonstrated promising survival in the phase II TYME-88-Panc study in patients with advanced pancreatic cancer.1,2 The oral modified dysfunctional tyrosine induced a median overall survival (OS) of 6.4 months in patients. The RECIST clinical benefit rate (CBR) of stable disease (SD) or better was 44% with available imaging, and there was a 92% …